Insider Selling: Bioventus Inc. (NYSE:BVS) SVP Sells 11,308 Shares of Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 11,308 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $5.84, for a total value of $66,038.72. Following the sale, the senior vice president now owns 81,630 shares of the company’s stock, valued at approximately $476,719.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Anthony D’adamio also recently made the following trade(s):

• On Thursday, April 11th, Anthony D’adamio sold 3,054 shares of Bioventus stock. The stock was sold at an average price of $4.75, for a total transaction of $14,506.50.

Bioventus Stock Performance

Shares of BVS opened at $5.67 on Monday. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.53 and a quick ratio of 0.97. The firm has a market cap of $448.89 million, a PE ratio of -16.20 and a beta of 0.89. Bioventus Inc. has a 1 year low of $2.70 and a 1 year high of $7.04. The stock’s fifty day moving average price is $5.60 and its two-hundred day moving average price is $5.17.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.12. The business had revenue of $129.46 million for the quarter, compared to the consensus estimate of $115.51 million. Bioventus had a negative net margin of 4.14% and a positive return on equity of 11.91%. On average, equities research analysts forecast that Bioventus Inc. will post 0.27 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on BVS shares. Canaccord Genuity Group increased their price objective on shares of Bioventus from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. Craig Hallum boosted their price objective on Bioventus from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 13th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of Bioventus in the first quarter worth about $28,000. Hillsdale Investment Management Inc. lifted its stake in Bioventus by 26.1% in the 1st quarter. Hillsdale Investment Management Inc. now owns 34,742 shares of the company’s stock worth $181,000 after purchasing an additional 7,200 shares in the last quarter. Lazard Asset Management LLC bought a new position in Bioventus in the 1st quarter valued at $40,000. GSG Advisors LLC grew its position in shares of Bioventus by 55.8% during the 1st quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock valued at $133,000 after purchasing an additional 9,500 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Bioventus in the first quarter worth $66,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.